Genmab A/S (NASDAQ:GMAB) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. reduced its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 20.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 74,502 shares of the company's stock after selling 18,776 shares during the quarter. PNC Financial Services Group Inc.'s holdings in Genmab A/S were worth $1,555,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently made changes to their positions in GMAB. Charles Schwab Investment Management Inc. raised its stake in shares of Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company's stock worth $636,000 after acquiring an additional 12,654 shares in the last quarter. AIMZ Investment Advisors LLC acquired a new position in Genmab A/S during the 4th quarter valued at about $3,525,000. HighTower Advisors LLC purchased a new stake in Genmab A/S in the third quarter valued at about $273,000. Verition Fund Management LLC acquired a new stake in Genmab A/S in the third quarter worth about $709,000. Finally, FMR LLC grew its stake in shares of Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after acquiring an additional 33,076 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Price Performance

NASDAQ:GMAB traded up $0.04 during trading hours on Wednesday, reaching $20.24. The company had a trading volume of 800,959 shares, compared to its average volume of 906,407. Genmab A/S has a 1-year low of $18.64 and a 1-year high of $31.02. The business's 50 day moving average price is $21.18 and its 200-day moving average price is $22.28. The firm has a market cap of $13.40 billion, a PE ratio of 11.63, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a research report on Thursday, February 13th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Finally, Truist Financial dropped their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $41.33.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.